Table 1.
SIR and AER for development of specific subsequent primary oral cancers among all 5-years cancer survivors in the PanCareSurFup cohort (N = 64,460).
| Type of SPN | Median age | Obs (%) | Exp | SIR (95% CI) | AER (95% CI) |
|---|---|---|---|---|---|
| Salivary gland | 27.8 | 64 (44%) | 3.7 | 17.2 (14.4–20.4) | 4.8 (4.0–5.7) |
| Tongue | 32.4 | 38 (26%) | 6.4 | 5.9 (4.7–7.4) | 2.5 (1.9–3.3) |
| Other oral cavity | 35.3 | 21 (14%) | 5.7 | 3.7 (2.7–5.0) | 1.2 (0.8–1.8) |
| Pharynx | 44.7 | 20 (14%) | 9.4 | 2.1 (1.6–2.9) | 0.8 (0.5–1.5) |
| Lip | 23.0 | 2 (1.4%) | 1.5 | 1.4 (0.5–3.6) | 0.0 (0.0–1.7) |
| Overall | 32.4 | 145 (100%) | 29.2 | 5.0 (4.4–5.6) | 9.2 (7.9–10.6) |
SPN subsequent primary malignant neoplasm, Obs observed, Exp expected, SIR standardised incidence ratio, CI confidence interval, AER absolute excess risks.